Document:

Share Purchase Agreement

 Exhibit 4.6 
 Dated May 28th, 2006 
 SIMCERE PHARMACEUTICAL CO.,LTD 
 INVESTING IN 
 YANTAI MEDGENN
CO.,LTD 
  

 SHARE
TRANSFER AGREEMENT 
  

  

 Share Transfer Agreement 
 Concerning Yantai Medgenn Co.,Ltd 
 THIS AGREEMENT is dated May 28th, 2006 and is made in Yantai, Shandong Province, People’s
Republic of China (“PRC”) BETWEEN: 
 Transferor: 
  

	 	1.	YANTAI RONGCHANG PHARMACEUTICAL CO.,LTD, a company with limited liability incorporated and existing under the laws of PRC whose registered office is at No.1 Rongchang Rd,
Yantai Economic & Technologic Development Area, Shandong (“Rongchang”); 

  

	 	2.	BEIJING ZHONGKECHENG DEVELOPMENT CO.,LTD, a company with limited liability incorporated and existing under the laws of PRC whose registered office is at South Side, No.5,
Chaoyang Bei Rd, Chaoyang District, Beijing(“Zhongkecheng”); 

  

	 	3.	YANTAI RUIKANG BIO-CHEMICAL PHARMACEUTICAL CO.,LTD, a company with limited liability incorporated and existing under laws of PRC whose registered office is at No.66, Shengli
Rd, Zhifu District, Yantai, Shandong(“ Ruikang”); 

 Aforesaid three (3) parties are collectively called
Transferor. 
 Transferee: 
 SIMCERE
PHARMACEUTICAL CO.,LTD, a company with limited liability incorporated and existing under laws of PRC whose registered office is at No.3, Jinlian Rd, Jinpan Industrial Area, Haikou, Hainan. 
 WHEREAS 
  

	1.	 YANTAI MEDGENN CO.,LTD (“YANTAI MEDGENN”) is a stock company jointly funded by the Transferor and other shareholders. YANTAI MEDGENN is
incorporated in accordance with relevant laws and has already gotten the Business License of Corporation of PRC ( Register Number: Qi Gu Lu Zong Fu Zi 003933-11). YANTAI 

	 	 
MEDGENN’s registered office is at No.1 Rongchang Rd, Yantai Economic & Technologic Development Area, Shandong. YANTAI MEDGENN’s registered
capital is RMB 30,128,100 divided into 30,128,150 shares. Rongchang owns 15,410,549 shares, Doctor Luo Yongzhang owns 10,599,083 shares, Doctor Zhou Bing owns 2,913,392 shares, ZHONGKECHENG owns 903,845 shares and RUIKANG owns 301,281 shares.

  

	2.	The Transferor agrees to transfer their respective shares and any and all rights, interest and obligation under said shares (“Targeted Shares”) to the Transferee in
accordance with this Agreement. 

  

	3.	The Transferee agrees to accept Targeted Shares from the Transferor in accordance with this Agreement. 

  

	 	NOW	THEREOF, parties hereto agree to deal with the share transfer between the Transferor and the Transferee as follows: 

 Article 1 Share Transfer 
 1.1 RONGCHANG agrees to
transfer to the Transferee and the Transferee agrees to accept from RONGCHANG, 15,410,549 shares in the capital of YANTAI MEDGENN in accordance with terms and conditions of this Agreement. 
 1.2 ZHONGKECHENG agrees to transfer to the Transferee, and the Transferee agrees to accept from ZHONGKECHENG, 903,845 shares in the capital of YANTAI
MEDGENN in accordance with terms and conditions of this Agreement. 
 1.3 RUIKANG agrees to transfer to the Transferee, and the Transferee
agrees to accept from RUIKANG, 301,281 shares in the capital of YANTAI MEDGENN in accordance with terms and conditions of this Agreement. 
 1.4 Upon the completion of share transfers under above paragraph 1.1 through paragraph 1.3, the Transferee shall totally own 16,615,675 shares in the capital of YANTAI MEDGENN. 
 1.5 Parties hereto agree, upon completing the registration of change with competent industrial and commercial administration concerning share transfers
under this Agreement, 

 
Targeted Shares and any and all rights and interest thereunder shall be deemed to be owned by the Transferee. The Transferee shall enjoy any and all rights
entitled by PRC laws to Targeted Shares which of course include rights to Hong Kong Medgeen Co.,Ltd, and undertake corresponding obligations, while the Transferor will no longer enjoy relevant rights and undertake relevant obligations unless
otherwise provided herein. 
 Article 2. Transfer Consideration and Payment Mode 
 2.1 Parties here to agree: 
 2.1.1 Under the
precondition that Targeted Shares and assets of YANTAI MEDGENN satisfy requirements provided herein, transfer price of Targeted Shares shall be RMB 8.15 per share, and the total transfer consideration shall be one hundred and thirty five
million four hundred and seventeen thousand seven hundred and fifty one point two five RMB yuan (RMB135,417,751.25); 
 2.1.2 The
consideration for Targeted Shares transferred by RONGCHANG shall be RMB125, 595, 974. 35; 
 2.1.3 The consideration for Targeted Shares
transferred by ZHONGKECHENG shall be RMB 7,366,336.75; 
 2.1.4 The consideration for Targeted Shares transferred by RUIKANG shall be RMB
2,455,440.15. 
 2.1.5 Aforesaid transfer consideration shall be the total consideration that the Transferee shall pay to the Transferor for
Targeted Shares. 
 2.2 Aforesaid transfer consideration shall be paid by the Transferee in installments in accordance with following time
schedule: 
 2.2.1 Within three (3) working days after the signature of this Agreement, the Transferee shall pay 20% of the total
consideration, equal to RMB27, 083, 550.25, to the Transferor. Said payment shall be remitted to the account designated by the Transferor; 
 2.2.2 Within two (2) weeks after the signature of this Agreement, the Transferee shall pay 40% of the total consideration, equal to RMB54, 167, 100.50, to the Transferor. Said payment shall be remitted to the account designated by the
Transferor; 
 2.2.3 After the Transferee actually manage YANTAI MEDGENN and achieve three (3) consecutive production batches of
qualified “Endostar” in accordance with specific technical documents and regulations, said products are confirmed after examination to satisfy output level and are submitted to competent authority for full examination, and the registration
of change concerning share transfers with competent industrial and commercial administration is completed, the Transferee shall pay 35% of the total consideration, equal to RMB 47,396,212.94, within three (3) weeks. Said payments shall be
remitted to the account designated by the Transferor; 

 2.2.4 Within one (1) week after the trial quality standards for “Endostar” become the
official quality standards with competent authorities’ approval supported by necessary documents filed by YANTAI MEDGENN under the management of the Transferee within required time period, the Transferee shall pay the rest 5% of the total
consideration, equal to RMB 6,770,887.56. Said payments shall be remitted to the account designated by the Transferor; 
 Article 3. Completion Date

 3.1 Completion of the transfer of Targeted Shares under this Agreement shall take place on the date when all of the following events happen, and said
date shall be the Completion Date: 
  

	 	(1)	This Agreement is legally and effectively signed by the Transferor and the Transferee; 

  

	 	(2)	The shareholder’s meeting of YANTAI MEDGENN pass a resolution to approve the share transfer under this Agreement, approve the Transferee to become a shareholder of YANTAI
MEDGENN and to hold Targeted Shares, and approve the registration of change concerning share transfers with competent industrial and commercial administration; 

  

	 	(3)	Share transfers obtain relevant approval from competent authorities; 

  

	 	(4)	Memorandum and articles of association of YANTAI MEDGENN is legally and properly amended so as to reflect the share transfer contemplated herein, and the Transferee is entered in
the amended memorandum and articles of association as the shareholder who owns 16,615,675 shares in YANTAI MEDGENN; 

  

	 	(5)	YANTAI MEDGENN files an application for the registration of change with competent industrial and commercial administration, and the Transferee is entered in the registration
documents of YANTAI MEDGENN as the shareholder who owns 16,615,675 shares in YANTAI MEDGENN; 

 3.2 Notwithstanding forgoing provisions under
paragraph 3.1, Parties hereto agree: 
  

	 	(1)	after the first installment of payment is made, the Transferee is entitled to dispatch officers to enter YANTAI MEDGENN to carry out relevant managements; 

 

	 	(2)	 after the second installment of payment is made, the Transferor, as controlling 

	 	 
shareholders of YANTAI MEDGENN, shall hand its actual controlling power to the Transferee; parties hereto shall actively cooperate with YANTAI MEDGENN to
finish the registration of change concerning share transfers with industrial and commercial administration as soon as possible; if necessary, the Transferee may engage an independent accounting firm recognized by the Transferor to carry out an audit
to YANTAI MEDGENN’s financial conditions; 

  

	 	(3)	after the Transferee actually manage YANTAI MEDGENN, the Transferor shall direct the Transferee to achieve three (3) consecutive production batches of qualified
“Endostar” in accordance with specific technical documents and regulations, and said products shall be confirmed to satisfy relevant standards by competent authority after examination. 

 Article 4. Intangibles 
 Under the precondition that
the patent situation concerning “Endostar” of YANTAI MEDGENN disclosed by the Transferor to the Transferee is true, YANTAI MEDGENN and the Transferee shall undertake all risks and liabilities arising from disputes related to patents of
“Endostar” after the share transfer, while the Transferor will not undertake any liabilities. 
 Article 5. Relationship with RONGCHANG

 5.1 After the controlling power and management right to YANTAI MEDGENN is handed to the Transferee, RONGCHANG shall be obligated to
provide any and all supporting facilities necessary for the normal management of YANTAI MEDGENN. RONGCHANG is entitled to charge YANTAI MEDGENN for costs and expenses arising from the provision of supporting facilities. YANTAI MEDGENN and RONGCHANG
shall enter into a special agreement for this issue. 
 5.2 After YANTAI MEDGENN moves into its new factory area, YANTAI MEDGENN may transfer
its land, houses and other real estates existing in RONGCHANG’s factory area to RONGCHANG at a price reasonable at the transfer time, and RONGCHANG shall accept said transfer. 
 Article 6. Confidential 
 6.1 The Transferor and the Transferee covenant and ensure to impose
restriction over 

 
their respective personnel, including their respective personnel dispatched to YANTAI MEDGENN and those personnel involved in the negotiation of this
Agreement not to disclose, before or after the signature of this Agreement, to a third party any and all confidential information about YANTAI MEDGENN they know as the shareholder of YANTAI MEDGENN or during the negotiation of this Agreement, except
that said confidential information is disclosed with the other party’s prior written authorization or based on the mandatory requirements of laws, administrative orders of PRC government, or judgment or ruling of competent judicial authorities.
Under such exception, the discloser shall disclose relevant information only to aforesaid approved or required extent, and submit the information to be disclosed to the other party for review before the disclosure. 
 6.2 Whether this Agreement is terminated or not, provisions under this Article 6 shall bind the Transferor forever. As for the Transferee, said
provisions shall survive until the Transferee’s termination right herein is excluded and terminated. 
 Article 7. Effectiveness and Termination

 7.1 This Agreement shall go into effect as from the date of signature. 
 7.2 The Transferee is entitled to unilaterally terminate this Agreement if any one or more of the following events occurs: 
  

	 	(1)	YANTAI MEDGENN does not own relevant technologies which was thought to have already been contributed after evaluation to YANTAI MEDGENN; 

  

	 	(2)	YANTAI MEDGENN’s existing patents and know-how can not support the industrial production of “Endostar”; or the first three (3) consecutive production batches of
products do not satisfy output level or are determined by competent authority after full examination not satisfying quality standards; 

  

	 	(3)	Because of any problem existing in the application procedure or relevant application contents concerning “Endostar” made by YANTAI MEDGENN before the signature of this
Agreement, the production and sale of “Endostar” is prohibited by relevant government authority. 

 7.3 In case any
event under paragraph 7.2 occurs, this Agreement shall be terminated as soon as the Transferee delivers a written notice thereof to the Transferor. 

 7.4 In case this Agreement is terminated in accordance with paragraph 7.2 and paragraph 7.3, within one
(1) week after receiving the termination notice, the Transferor shall refund to the Transferee all consideration it has received together with interests at corresponding bank’s lending rate from the date the Transferee paid the
consideration until the date the Transferor refund all consideration it has received. The Transferee shall return Targeted Shares to the Transferor and provide assistance in relevant registration of change. 
 7.5 Parties hereto agree in consensus that the Transferor is entitled to unilaterally terminate this Agreement if the Transferee does not pay the
transfer consideration in accordance with relevant time schedule. Under such condition, this Agreement shall be terminated as soon as the Transferor delivers a written notice thereof to the Transferee. 
 7.6 In case this Agreement is terminated in accordance with paragraph 7.5, the Transferee shall pay a default fine equal to 1% of the total transfer
consideration to the Transferor and the said default fine may be directly deducted from the transfer consideration refunded by the Transferor. 
 Article
8. Cost 
 Any and all taxes, costs and expenses arising from the execution and performance of this Agreement shall be borne and paid in
accordance with relevant laws and regulations. 
 Article 9. Transferor and Transferee 
 9.1 Three (3) companies as the Transferor shall undertake joint and several liabilities to each other for any and all obligations under this
Agreement. Any one company may act for and on behalf of the other two (2) companies. 
 9.2 To facilitate the share transfer, the
Transferee shall be entitled to appoint its affiliates to accept any or all transferred shares. The actual transferee shall duly enjoy relevant rights and undertake relevant obligations under this Agreement. The Transferor shall assist the
Transferee to handle relevant formalities. 
 Article 10. Employee Settlement 
 10.1 The Transferor and the Transferee agree in consensus that any and all employees’ 

 
interest shall be respected and safeguarded when carry out share transfer. Moreover, parties hereto agree that the stabilization of employee team shall be a
compound part of the intrinsic value of YANTAI MEDGENN. Therefore, the employee team shall be kept stable after this Agreement is performed. 
 10.2 After actually getting the controlling powers and management rights of YANTAI MEDGENN, the Transferee shall safeguard employees’ interest strictly in accordance with labor laws and regulations, and shall not unreasonably dismiss
any employee who is within the labor contract period. 
 10.3 The Transferor shall also play an active and positive role in stabilize the
employee team of YANTAI MEDGENN. The Transferor or its affiliates shall not engage any employee of YANTAI MEDGENN without the Transferee’s prior consent. Parties hereto shall negotiate on the work handover and the change of employment of those
employees who are dispatched by the Transferor to YANTAI MEDGENN. 
 Article 11. Default Responsibilities 
 11.1 Any of the following conditions of either party hereto shall constitute a breach to this Agreement: 
  

	 	(1)	failure to perform any obligations provided under this Agreement; 

  

	 	(2)	failure to comply with representations and warranties made to the other party in Schedule I and Schedule II; 

  

	 	(3)	representations and warranties made in this Agreement containing untrue or misleading contents(no matter in goodwill or mala fide). 

 11.2 Unless otherwise provided, in case of a breach, the observing party shall be entitled to demand the default party to correct relevant defaults
within thirty (30) days; if the default party does not make correction within required time period and make the realization of the purpose of this Agreement impossible, the observing party shall be entitled to terminate this Agreement.

 11.3 Parties hereto covenant to each other that, whether this Agreement is terminated or not, the default party shall, upon the request of
the observing party, compensate the observing party as follows, which shall not impair the observing party’s right to claim damages to the default party for its default: 
  

	 	(1)	some money equal to the amount that could make the observing party recover to the situation it should have being if the default party had not defaulted; 

	 	(2)	observing party’s losses arising directly or indirectly from the default party’s default (including reasonable legal costs, arbitration costs and attorney fees paid by the
observing party). 

 11.4 Members of the Transferor shall undertake joint and several liabilities to each other for any and all
default responsibilities under this Agreement. 
 11.5 Either party’s failure to exercise or delay in exercising its right provided by
this Agreement does not constitute a waiver of such right, and the partial exercise of such right shall not prevent full exercise of such right. 
 Article 12. Force Majeure 
 12.1 In case either party’s nonperformance or delay in performance of obligation provided in
this Agreement is caused by the force majeure, such party shall be exempted from any and all default responsibilities. The force majerure as used herein means those events that are not attributable to either party of this Agreement, unpredictable at
the time signing this Agreement, and their occurrences are unavoidable and relevant subsequences are insurmountable. 
 12.2 Once force
majeure occurs, the influenced party shall, if possible, notify the force majeure to the other party in time within five (5) working days. In case the influenced party fails to perform such notification obligation and its nonperformance
therefore cause losses to the other party, the influenced party shall compensate the other party for losses arising therefrom. Upon the force majerue disappears, the party who is once influenced by the force majeure and fails to perform this
Agreement shall use its best efforts to resume its performance of obligations provided herein. 
 Article 13. Governing Law 
 The conclusion, validity, interpretation and performance of this Agreement and the settlement of disputes arising thereof shall be governed by laws of
PRC. 
 Article 14. Witness 
 Parties
hereto agree in consensus that the Administrative Committee of Yantai Economic & Technologic Development Area shall be the witness of this Agreement, and shall supervise and coordinate the effective implementation of this Agreement.

 The Administrative Committee of Yantai Economic & Technologic Development Area covenants that
government’s preferential policies, supports and assistances provided to YANTAI MEDGENN as an incentive to encourage YANTAI MEDGENN to be an innovative enterprise will remain unchanged, and the government will continue support YANTAI MEDGENN in
research and development, manufacturing, management and operation in future. 
 Article 15. Dispute Resolution Forum 
 15.1 If there is any dispute arising from, related to or in connection with this Agreement, parties hereto shall first attempt to resolve such dispute
through friendly consultations. In case such dispute cannot be resolved through consultation, either party shall be entitled to submit such dispute to China International Economic and Trade Arbitration Commission for arbitration. The arbitration
shall be carried out in accordance with such commission’s arbitration rules then in effect, and the award shall be final and binding over parties hereto. 
 15.2 During the arbitration, except for those disputed issues submitted for arbitration, parties hereto shall go on performing remained obligations herein. 
 Article 16. Miscellenous 
 16.1 The schedules form
part of this Agreement and shall have same effect as provisions of this Agreement. 
 16.2 Any amendment to this Agreement may be made only
by a written instrument signed by parties hereto. The amended or supplemented provisions shall form part of this Agreement. 
 16.3 This
Agreement shall inure for the benefit of and be binding upon parties hereto and their respective successors and assigns. 
 16.4 In case any
provision of this Agreement is determined to be invalid by the arbitral tribunal, the validity of the remained provisions shall not in any way be affected or impaired thereby. 

 16.5 This Agreement constitutes the entire agreement concerning the transfer of shares in YANTAI MEDGENN
and relevant issues, and shall supersede any and all previous draft agreements, intention, agreements, promises, statements and arrangements, whether written or oral, between parties hereto. 
 16.6 All notices hereunder shall be in writing and in Chinese, and shall be sent by registered post or facsimile transmission or other electronic
communication. Notices shall be deemed to have been duly given only if sent to parties hereto at their respective registered office. If such notices are delivered by registered post, such notices shall be deemed given on the date indicated in the
return receipt. If such notices are delivered by facsimile transmission, such notices shall be deemed given on the date indicated in the transmittal confirmation. 
 16.7 This Agreement shall be executed in eight (8) counterparts, and each party hereto shall keep one (1) counterpart and the Witness shall keep one (1) counterpart. The rest three (3) counterparts
shall be used to file relevant applications to competent examining and approving authorities. 
 16.8 IN WITNESS WHEREOF, the parties to this
Agreement have executed this Agreement at the place and as of the date first above written. 

 (Signature Page) 
 Transferor: 
 YANTAI RONGCHANG PHARMACEUTICAL CO., LTD 
 Legal / Duly Authorized Representative: 
 BEIJING ZHONGKECHENG DEVELOPMENT CO., LTD 
 Legal / Duly Authorized Representative: 
 YANTAI RUIKANG BIO-CHEMICAL PHARMACEUTICAL CO., LTD 
 Legal / Duly Authorized Representative: 
 Transferee: 
 SIMCERE PHARMACEUTICAL CO., LTD 
 Legal / Duly Authorized Representative: 
 Witness: 
 ADMINISTRATIVE COMMITTEE OF YANTAI ECONOMIC & TECHNOLOGIC DEVELOPMENT AREA 
 Legal / Duly Authorized Representative:

 Schedule I: Transferee’s Representations and Warranties 
 The Transferee hereby makes following representations and warranties to the Transferor: 
 1. The Transferee is a company with limited liability incorporated and existing under the laws of PRC, and has any and all rights, authorities and capabilities necessary for the undertaking and performance of all
obligations and liabilities hereunder. This Agreement, when executed, shall be legally and effectively binding over the Transferee. 
 2. The signature and
performance of this Agreement and relevant documents did not in the past, does not now or will not in future cause the Transferee to: 
 (1) violate its
articles of association; 
 (2) violate any agreements binding the Transferee; 
 (3) violate any order, judgment or adjunction binding the Transferee, which is made by competent government authorities, courts and arbitral tribunal; or 
 (4) need a third party’s consent. 
 3. The Transferee shall perform its obligation concerning the payment of the
transfer consideration in accordance with relevant provisions hereunder, and shall assure the legality of the fund resources. 

 Schedule II: Transferor’s Representations and Warranties 
 The Transferor hereby makes following representations and warranties to the Transferee: 
 I. General 
 1. The Transferor guarantees that any and all information given to the Transferee during the Due Diligence is
true and accurate, objectively and fairly reflects financial conditions, business and managements of YANTAI MEDGENN as of the date of this Agreement, and there is no material omission, disguise or misleading representations or statements that might
affect its trueness and accuracy. 
 2. YANTAI MEDGENN is a stock company incorporated and existing under PRC laws, all its investments has already been
fully contributed and whose capital will remain in full, and all its assets and business are legally and effectively owned, used and operated. 
 3. In
respect of shares in YANTAI MEDGENN, no third party is granted purchase option, swap rights, pre-emptive rights and other rights. There is no share incentives or share option arrangements involving any director or employee in YANTAI MEDGENN.

 4. Shareholders’ Agreement and Articles of Association, as amended, of YANTAI MEDGENN has already listed all rights and restriction concerning its
shareholders. YANTAI MEDGENN’s shareholders have already performed their respective obligations under Shareholders’ Agreement and Articles of Association. Entire copy of such Shareholders’ Agreement and Articles of Association has
already been delivered to the Transferee. 
 5. Except for those disclosed matters, the Transferor is not aware that there are any existing or threatening
disputes or claims concerning Shareholders’ Agreement and Articles of Association, as amended, of YANTAI MEDGENN or any issues which may incur such disputes or claims. 
 6. All of companies under the Transfer are companies with limited liability incorporated and existing under the laws of PRC, and has any and all rights, authorities and capabilities necessary for the undertaking and
performance of all obligations and liabilities hereunder. This Agreement, when executed, shall be legally and effectively binding over the Transferor. 

 7. The signature and performance of this Agreement and relevant documents did not in the past, does not now or will not
in future cause the Transferor to: 
 (1) violate their respective articles of association; 
 (2) violate any agreements binding the Transferor; 
 (3) violate any order, judgment or adjunction binding the Transferor,
which is made by competent government authorities, courts and arbitral tribunal; or 
 (4) need a third party’s consent (except for those that have
already been disclosed). 
 8. Companies under the Transferor have legal and full ownership to their respective shares in YANTAI MEDGENN, all of which are
free from any charge, pledge or other encumbrances. Said companies have full legal capacities and rights to perform any and all obligations under this Agreement and do not suffer any restrictions from a third party other than mandatory restriction.
Any and all consents, permissions, approvals, registrations, exemptions and notification were gotten before the date of this Agreement. 
 9. The signature
and subsequent performance of this Agreement will not cause any material adverse effects to YANTAI MEDGENN’s material assets and activities concerning manufacturing, operation, sale, or cause YANTAI MEDGENN to lose any approval, rights,
preferential treatments and important clients or suppliers that it had before the date of this Agreement. 
 II. Assets 
 YANTAI MEDGENN’s assets, including real estates, are legally owned and in good condition. Except otherwise disclosed to the Transferee in the assets list, such
assets are free of influence of any lien (except for those outstanding debts arising from current assets sold in accordance with commercial price and terms or woks undertaken in ordinary business operation), mortgage, pledge, lease, license or other
encumbrance or any third party’s rights, conditions, rules or other restrictions, which will or may cause material adverse effects to the value of such assets or YANTAI MEDGENN’s abilities to use, transfer or sell such assets. 

III. Financial Issues 
 YANTAI
MEDGENN’s financial statements provided by the Transferor to the Transferee objectively reflect YANTAI MEDGENN’s assets, liabilities and operation results as of April 30th, 2006, and do not contain any material mistake or discrepancy. 

 IV. Operating Business 
 1.
Unless otherwise provided herein, YANTAI MEDGENN has already gotten any and all powers, authorizations, permissions and consents necessary for its business operation, and there are no matters that violate or may violate such powers, authorizations,
permissions and consents, or cause such powers, authorizations, permissions and consents or any license to be revoked or withdrawn, which may cause material adverse effects to YANTAI MEDGENN. 
 2. Unless otherwise provided herein, all of YANTAI MEDGENN’s activities concerning manufacturing, operation and sale comply with provisions of PRC laws and its
Articles of Association, and will not cause any harm to a third party’s rights. YANTAI MEDGENN did not sign any agreement which might restrict its business operation. 
 3. Unless otherwise disclosed to the Transferee, the Transferor, its affiliated companies, its employees dispatched to YANTAI MEDGENN did not and will not own, by any means, any direct or indirect rights or interests
in any business which compete or may compete with YANTAI MEDGENN’s main business, and there is no related-party transaction between the Transferor, its affiliated companies, the Transferor’s employees that are not disclosed to the
Transferee yet. 
 V. Taxation 
 Before the effective date of
this Agreement, YANTAI MEDGENN has already and will continue to pay to taxation authority or other competent authority in P.R.C or elsewhere the taxation due or payable arising from or in respect of its business, assets and liabilities. 

VI. Disputes, Debt, Litigations, Arbitrations 
 1. Unless otherwise
provided herein, all agreements in which YANTAI MEDGENN is a party are necessary for its normal business. Unless otherwise disclosed to the Transferee, to the knowledge of YANTAI MEDGENN, YANTAI MEDGENN is not aware of any existing claims or any
matters which might cause material potential claims, or cause material harm to YANTAI MEDGENN or its shareholders’ interests. 

 2. Unless otherwise disclosed, YANTAI MEDGENN has no other debt, potential debt, contingent debt. 
 3. YANTAI MEDGENN’s operation complies with relevant laws and local regulations in all material respects, there is no administrative order, adjudication or award
which may cause materially adverse effects to YANTAI MEDGENN’s assets or business, and there is no pending material litigation or arbitration. 
 4.
There is no seizure, attachment, enforcement or other procedures, for example insolvency and liquidation, involving YANTAI MEDGENN’s assets. 
 VII.
Insurance 
 YANTAI MEDGENN maintains insurance policies covering its operating assets with proper cautiousness, and has already implemented social insurance
for its employees in accordance with requirements of relevant laws and regulations. 
 VIII. Intellectual Property 
 1. The representations concerning Endostar’s patent rights made by the Transferor to the Transferee are true (The Transferor shall list all conditions concerning
Endostar’s patent rights in the list of intangibles attached to this Agreement). 
 2. All know-how, copyrights, trademarks and other similar
intellectual property rights (the patent rights shall be subject to special articles provided herein), which are or may be important to YANTAI MEDGENN’s operation, are legally or actually owned by or exclusively licensed to YANTAI MEDGENN. In
addition, such rights shall be free of any restriction from a third party. 
 3. YANTAI MEDGENN’s proprietary confidential core technology, Protein
Renaturation Technology, shall be kept in writing. Such technology could be fully grasped, by reading said written record, by a person with due authorization other than the key technician who now grasps such technology so as to satisfy YANTAI
MEDGENN’s manufacturing. 
 4. To sell Endostar overseas, YANTAI MEDGENN’s has already carried out overseas cooperation and correspondingly granted
some authorization concerning Endostar’s overseas registration and overseas sale. Such cooperation and authorization shall not affect YANTAI MEDGENN’s ownership to Endostar and relevant patents and know-how. 

 IX. Interval 
 1. During the
period from the signing date of this Agreement to the completion date of the registration of change with competent industrial and commercial administration (“Interval”), YANTAI MEDGENN shall: 
 (1) operate legally and normally and abide by all agreement it signed as before; 
 (2) maintain the legal existence of YANTAI MEDGENN and pay taxation in accordance with relevant laws; and 
 (3) keep all documents correct and full.

 2. During the Interval, unless getting the Transferee’s prior written consent, the Transferor and YANTAI MEDGENN shall not do any things which are
subject to the approved of the board of directors. 
 3. During the Interval, if any matter occurs, which will cause material change or effects to the
representations and warranties made by the Transferor, the Transferor shall promptly disclose such matter to the Transferee in writing. 

 Schedule III: Some Opinions Regarding Relevant Matters Between YANTAI MEDGENN and Rongchang 
 After acquiring controlling shares in YANTAI MEDGENN and actually managing YANTAI MEDGENN, the Transferee shall cause the board of directors make
resolutions so as to deal with relevant matters between YANTAI MEDGENN and Rongchang as below: 
 I. There are two sets of TR-86 liquid oral
drug filling equipments among YANTAI MEDGENN’s fixed assets. YANTAI MEDGENN’s recent production does not need such equipments. Parties hereto hereby agree that Rongchang purchase such equipments with a consideration of RMB two
(2) million. Rongchang shall pay said consideration to YANTAI MEDGENN within one (1) week after YANTAI MEDGENN confirms this issue. 
 II. YANTAI MEDGENN now own facilities and relevant land-use right within Rongchang’s factory area. YANTAI MEDGENN may sell said facilities and relevant land-use right at the price of RMB 3 million to Rongchang within three
(3) years as from the signing date of this Agreement, and Rongchang shall accept. If exceeding said three (3) years, YANTAI MEDGENN and Rongchang shall otherwise consult with each other. 
 RMB 1.5 million shall be paid within one week as from the date the purchase and sale agreement is signed, while the other RMB 1.5 million shall
be paid within one week as from the date relevant transfer formalities are finished.Form of Indemnification Agreement with the Registrant's directors

 Exhibit 10.1 
 INDEMNIFICATION AGREEMENT 
 This Indemnification Agreement (the “Agreement”) is entered
into as of                      by and between Simcere Pharmaceutical Group, a Cayman Islands company (the “Company”) and the
undersigned, a [director or officer] of the Company (“Indemnitee”). 
 RECITALS 
 1. The Company recognizes that highly competent persons are becoming more reluctant to serve corporations as directors or in other capacities unless they
are provided with adequate protection through insurance or adequate indemnification against risks of claims and actions against them arising out of their services to the corporation. 
 2. The Board of Directors of the Company (the “Board”) has determined that the inability to attract and retain highly competent persons to
serve the Company is detrimental to the best interests of the Company and its shareholders and that it is reasonable and necessary for the Company to provide adequate protection to such persons against risks of claims and actions against them
arising out of their services to the corporation. 
 3. The Company and Indemnitee do not regard the indemnities available under the
Company’s current memorandum and articles of association (the “Articles of Association”) as adequate to protect Indemnitee against the risks associated with his service to the Company. 
 4. The Company is willing to indemnify Indemnitee to the fullest extent permitted by applicable law, and Indemnitee is willing to serve and continue to
serve the Company on the condition that he be so indemnified. 
 AGREEMENT 
 In consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: 
 I. Definitions 
 The following terms shall have the
meanings defined below: 
 Disinterested Director means a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee. 
 Change in Control shall be deemed to have occurred if, on or after the
date of this Agreement, (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than (a) a trustee or other fiduciary holding
securities under an employee benefit plan of the Company acting in such capacity; (b) a corporation owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of ordinary shares of
the Company; or (c) any current beneficial shareholder or group, as defined by Rule 13d-5 of the Exchange Act, including the heirs, assigns and successors thereof, of beneficial ownership, within the meaning of Rule 13d-3 of the Exchange Act,
of securities possessing more than 50% of the total combined voting power of the Company’s outstanding securities; hereafter becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of the Company representing more than 20% of the total combined 

 
voting power represented by the Company’s then outstanding ordinary shares, (ii) during any period of two consecutive years, individuals who at the
beginning of such period constitute the Board and any new director whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least two thirds (2/3) of the directors then still in
office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii) the shareholders of the Company approve a
merger or consolidation of the Company with any other corporation other than a merger or consolidation which would result in the ordinary shares of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into ordinary shares of the surviving entity) at least 80% of the total voting power represented by the ordinary shares of the Company or such surviving entity outstanding immediately after such merger or
consolidation, or the shareholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of related transactions) all or substantially all
of the Company’s assets. 
 Expenses shall include damages, judgments, fines, penalties, settlements and costs, attorneys’
fees and disbursements and costs of attachment or similar bond, investigations, liabilities, losses, taxes, any expenses paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or
preparing for any of the foregoing in, any Proceeding, and any taxes, interests, assessments or other charges imposed as a result of the actual or deemed receipt of any payments under this Agreement. 
 Indemnifiable Event means any event or occurrence that takes place either before or after the execution of this Agreement, related to the fact
that Indemnitee is or was a director or an officer of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other entity, including
services with respect to employee benefit plans, or was a director or officer of an entity that was a predecessor of the Company or another entity at the request of such predecessor entity, or related to anything done or not done by Indemnitee in
any such capacity. 
 Independent Counsel means a law firm, or a member of a law firm, that is experienced in matters of corporation
law and neither presently is, nor in the past five (5) years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this
Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent
Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s
rights under this Agreement. 
 Participant means a person who is a party to, or witness or participant (including on appeal) in, a
Proceeding. 
 Proceeding means any threatened, pending, or completed action, suit or proceeding, or any inquiry, hearing or
investigation, whether civil, criminal, administrative, investigative or other, including any appeal thereof, in which Indemnitee may be or may have been involved as a party or otherwise by reason of an Indemnifiable Event, including, without
limitation, any threatened, pending, or completed action, suit or proceeding by or in the right of the Company. 
  

 2 

 Reviewing Party means (A) the Board by a majority vote of a quorum consisting of
Disinterested Directors, or (B) if a quorum of the Board consisting of Disinterested Directors is not obtainable or, even if obtainable, said Disinterested Directors so direct, Independent Counsel in a written opinion to the Board, a copy of
which shall be delivered to Indemnitee. 
 II. Agreement To Indemnify 
 1. General Agreement. In the event Indemnitee was, is, or becomes a Participant in, or is threatened to be made a Participant in, a Proceeding, the Company shall indemnify the Indemnitee from and against any
and all Expenses which Indemnitee incurs or becomes obligated to incur in connection with such Proceeding, to the fullest extent permitted by applicable law. 
 2. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for a portion of Expenses, but not for the total amount of Expenses, the Company
shall indemnify the Indemnitee for the portion of such Expenses to which Indemnitee is entitled. 
 3. Exclusions. Notwithstanding
anything in this Agreement to the contrary, Indemnitee shall not be entitled to indemnification under this Agreement: 
 (a) to the extent
that payment is actually made to Indemnitee under a valid, enforceable and collectible insurance policy; 
 (b) to the extent that Indemnitee
is indemnified and actually paid other than pursuant to this Agreement; 
 (c) in connection with any Proceeding initiated by Indemnitee
against the Company, any director or officer of the Company or any other party, and not by way of defense, unless (i) the Company has joined in or the Reviewing Party (as hereinafter defined) has consented to the initiation of such Proceeding;
or (ii) the Proceeding is one to enforce indemnification rights under this Agreement or any applicable law; 
 (d) for a disgorgement of
profits made from the purchase and sale by the Indemnitee of securities pursuant to Section 16(b) of the Exchange Act or similar provisions of any applicable U.S. state statutory law or common law; 
 (e) brought about by the dishonesty or fraud of the Indemnitee seeking payment hereunder; provided, however, that the Indemnitee shall be protected under
this Agreement as to any claims upon which suit may be brought against him by reason of any alleged dishonesty on his part, unless a judgment or other final adjudication thereof adverse to the Indemnitee establishes that he committed (i) acts
of active and deliberate dishonesty, (ii) with actual dishonest purpose and intent, and (iii) which acts were material to the cause of action so adjudicated; 
 (f) for any judgment, fine or penalty which the Company is prohibited by applicable law from paying as indemnity; 
 (g) arising out of Indemnitee’s personal tax matter; or 
  

 3 

 (h) arising out of Indemnitee’s breach of an employment agreement with the Company (if any) or any
other agreement with the Company or any of its subsidiaries. 
 4. No Employment Rights. Nothing in this Agreement is intended to
create in Indemnitee any right to continued employment with the Company. 
 5. Contribution. If the indemnification provided in this
Agreement is unavailable and may not be paid to Indemnitee for any reason other than those set forth in Section II. 3, then the Company shall contribute to the amount of Expenses paid in settlement actually and reasonably incurred and paid or
payable by Indemnitee in such proportion as is appropriate to reflect (i) the relative benefits received by the Company on the one hand and by the Indemnitee on the other hand from the transaction from which such Proceeding arose, and
(ii) the relative fault of the Company on the one hand and of the Indemnitee on the other hand in connection with the events which resulted in such Expenses, as well as any other relevant equitable considerations. The relative fault of the
Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent the circumstances
resulting in such Expenses, judgments, fines or settlement amounts. The Company agrees that it would not be just and equitable if contribution pursuant to this Section II. 5 were determined by pro rata allocation or any other method of allocation
which does not take account of the foregoing equitable considerations. 
 III. Indemnification Process 
 1. Notice and Cooperation By Indemnitee. Indemnitee shall give the Company notice in writing as soon as practicable of any claim made against
Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be given in accordance with Section VI.7 below. In addition, Indemnitee shall give the Company such information and cooperation as the
Company may reasonably request. 
 2. Indemnification Payment. 
 (a) Advancement of Expenses. Indemnitee may submit a written request with reasonable particulars to the Company requesting that the Company advance
to Indemnitee all Expenses that may be reasonably incurred in advance by Indemnitee in connection with a Proceeding. The Company shall, within ten (10) business days of receiving such a written request by Indemnitee, advance all requested
Expenses to Indemnitee. Any excess of the advanced Expenses over the actual Expenses will be repaid to the Company. 
 (b) Reimbursement
of Expenses. To the extent Indemnitee has not requested any advanced payment of Expenses from the Company, Indemnitee shall be entitled to receive reimbursement for the Expenses incurred in connection with a Proceeding from the Company as soon
as practicable after Indemnitee makes a written request to the Company for reimbursement. 
 (c) Determination by the Reviewing Party.
Notwithstanding the foregoing, (i) the obligations of the Company under Section II.1 shall be subject to the condition that the Reviewing Party shall not have determined (in a written opinion, in any case in which the Independent Counsel
referred to in Section III.2(e) hereof is involved) that Indemnitee would not be permitted to be indemnified under applicable law or the Company’s 

  

 4 

 
Articles of Association, and (ii) the obligation of the Company to make an advance payment of Expenses to Indemnitee pursuant to Section III. 2(a) shall
be subject to the condition that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law or the Company’s Articles of Association, the Company shall be
entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences legal proceedings in a court of competent
jurisdiction to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and
Indemnitee shall not be required to reimburse the Company for any advanced Expenses until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). The Indemnitee’s
obligation to reimburse the Company for any advanced Expenses shall be unsecured and no interest shall be charged thereon. If there has not been a Change in Control, the Reviewing Party shall be selected by the Board, and if there has been such a
Change in Control (other than a Change in Control which has been approved by a majority of the Company’s Board who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent Counsel referred to in
Section III.2(e) hereof. 
 (d) Enforcement of Indemnification Rights. If there has been no determination by the Reviewing Party or if
the Reviewing Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law, or if Indemnitee has not otherwise been paid in full within 30 days after a written demand has been
received by the Company, Indemnitee shall have the right to commence litigation in any court having subject matter jurisdiction thereof and in which venue is proper to recover the unpaid amount of the demand (an “Enforcement Proceeding”)
and, if successful in whole or in part, Indemnitee shall be entitled to be paid any and all Expenses in connection with such Enforcement Proceeding. The Company hereby consents to service of process and to appear in any such proceeding. 

(e) Change in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has been
approved by a majority of the Company’s Board who were directors immediately prior to such Change in Control) then, with respect to all matters thereafter arising concerning the rights of Indemnitees to payments of Expenses under this Agreement
or any other agreement or under the Company’s Articles of Association as now or hereafter in effect, Independent Counsel shall be selected by the Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such
counsel, among other things, shall render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law, and the Company agrees to abide by such opinion. The
Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities and damages arising out of or relating to
this Agreement or its engagement pursuant hereto. 
 3. Assumption of Defense. In the event the Company is obligated under this
Agreement to advance or bear any Expenses for any Proceeding against Indemnitee, the Company shall be entitled to assume the defense of such Proceeding, with counsel approved by Indemnitee, upon delivery to Indemnitee of written notice of its
election to do so. After 

  

 5 

 
delivery of such notice, approval of such counsel by Indemnitee in writing and the retention of such counsel by the Company, the Company will not be liable
to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same Proceeding, unless (i) the employment of counsel by Indemnitee has been previously authorized by the Company,
(ii) Indemnitee shall have reasonably concluded that, based on written advice of counsel, there may be a conflict of interest of such counsel retained by the Company between the Company and Indemnitee in the conduct of any such defense, or that
counsel selected by the Company may not be adequately representing Indemnitee, or (iii) the Company ceases or terminates the employment of such counsel with respect to the defense of such Proceeding, in any of which events the fees and expenses
of Indemnitee’s counsel shall be at the expense of the Company. At all times, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee’s expense. 
 4. Defense to Indemnification, Burden of Proof and Presumptions. It shall be a defense to any action brought by Indemnitee against the Company to
enforce this Agreement that it is not permissible under this Agreement or applicable law for the Company to indemnify the Indemnitee for the amount claimed. In connection with any such action or any determination by the Reviewing Party or otherwise
as to whether Indemnitee is entitled to be indemnified under this Agreement, the burden of proving such a defense or determination shall be on the Company. Neither the failure of the Reviewing Party or the Company to have made a determination prior
to the commencement of such action by Indemnitee that indemnification is proper under the circumstances because Indemnitee has met the standard of conduct set forth in applicable law, nor an actual determination by the Reviewing Party or the Company
that Indemnitee had not met such applicable standard of conduct shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 
 5. No Settlement Without Consent. Neither party to this Agreement shall settle any Proceeding in any manner that would impose any damage, loss,
penalty or limitation on Indemnitee without the other party’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold its consent to any proposed settlement. 
 6. Company Participation. Subject to Section II.5, the Company shall not be liable to indemnify the Indemnitee under this Agreement with regard to
any judicial action if the Company was not given a reasonable and timely opportunity, at its expense, to participate in the defense, conduct and/or settlement of such action. 
 IV. Director and Officer Liability Insurance 
 1. Liability Insurance. The Company shall obtain
and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses incurred in connection with their services to the Company or to ensure the Company’s
performance of its indemnification obligations under this Agreement. To the extent the Company determines that it is no longer practicable for the Company to maintain such insurances, it shall notify promptly its directors and officers before it
terminates such insurances and such termination must be approved by the majority of the Company’s directors. 
 2. Coverage of
Indemnitee. To the extent the Company maintains an insurance policy or policies providing directors’ and officers’ liability insurance, Indemnitee shall be covered by such policy or policies, in accordance with its or their terms, to
the maximum extent of the coverage available for any of the Company’s directors or officers. 
  

 6 

 3. No Obligation. Notwithstanding the foregoing, the Company shall have no obligation to obtain or
maintain any director and officer insurance policy if a majority of the Company’s directors determines in good faith that such insurance is not reasonably available in the case that (i) premium costs for such insurance are disproportionate
to the amount of coverage provided, (ii) the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or (iii) Indemnitee is covered by similar insurance maintained by a parent or subsidiary of
the Company. 
 V. Non-Exclusivity; Federal Preemption; Term 
 1. Non-Exclusivity. The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Articles of Association, any vote of shareholders or
directors, applicable law or any written agreement between Indemnitee and the Company (including its subsidiaries and affiliates). The indemnification provided under this Agreement shall continue to be available to Indemnitee for any action taken or
not taken while serving in an indemnified capacity even though he may have ceased to serve in any such capacity at the time of any Proceeding. 
 2. Federal Preemption. Notwithstanding the foregoing, both the Company and Indemnitee acknowledge that in certain instances, U.S. federal law or public policy may override applicable law and prohibit the Company from indemnifying its
directors and officers under this Agreement or otherwise. Such instances include, but are not limited to, the U.S. Securities and Exchange Commission’s prohibition on indemnification for liabilities arising under certain U.S. federal securities
laws. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the
Company’s right under public policy to indemnify Indemnitee. 
 3. Duration of Agreement. All agreements and obligations of the
Company contained herein shall continue during the period Indemnitee is an officer and/or a director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding by reason of his former or current capacity at the Company or any other enterprise, including service with respect to
employee benefit plans) at the Company’s request, whether or not he is acting or serving in any such capacity at the time any Expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall continue in
effect regardless of whether Indemnitee continues to serve as an officer and/or a director of the Company or any other enterprise at the Company’s request. 
 VI. Miscellaneous 
 1. Amendment of this Agreement. No supplement, modification, or amendment of this Agreement shall
be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall operate as a waiver of any other provisions (whether or not similar), nor shall such waiver constitute a continuing waiver.
Except as specifically provided in this Agreement, no failure to exercise or any delay in exercising any right or remedy shall constitute a waiver. 
  

 7 

 2. Subrogation. In the event of payment to Indemnitee by the Company under this Agreement, the
Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such
documents necessary to enable the Company to bring suit to enforce such rights. 
 3. Assignment; Binding Effect. Neither this
Agreement nor any of the rights or obligations hereunder may be assigned by either party hereto without the prior written consent of the other party; except that the Company may, without such consent, assign all such rights and obligations to a
successor in interest to the Company which assumes all obligations of the Company under this Agreement in a written agreement in form and substance satisfactory to Indemnitee. Notwithstanding the foregoing, this Agreement shall be binding upon and
inure to the benefit of and be enforceable by and against the parties hereto and the Company’s successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially all of the business
and/or assets of the Company) and assigns, as well as Indemnitee’s spouses, heirs, and personal and legal representatives. 
 4.
Severability and Construction. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to a court
order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. In addition, if any portion of this Agreement shall be held by a court of competent jurisdiction to be invalid, void, or otherwise unenforceable,
the remaining provisions shall remain enforceable to the fullest extent permitted by applicable law. The parties hereto acknowledge that they each have opportunities to have their respective counsels review this Agreement. Accordingly, this
Agreement shall be deemed to be the product of both of the parties hereto, and no ambiguity shall be construed in favor of or against either of the parties hereto. 
 5. Counterparts. This Agreement may be executed in two counterparts, both of which taken together shall constitute one instrument. 
 6. Governing Law. This agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of
the State of New York, U.S.A., without giving effect to conflicts of law provisions thereof. 
 7. Notices. All notices, demands, and
other communications required or permitted under this Agreement shall be made in writing and shall be deemed to have been duly given if delivered by hand, against receipt, on the date of delivery, or mailed, on the third business day after mailing,
postage prepaid, certified or registered mail, return receipt requested, and addressed to the Company at: 
 Simcere Pharmaceutical Group

 No.699-18 Xuan Wu Avenue 
 Xuan
Wu District, Nanjing 
 Jiangsu Province 210042 
 People’s Republic of China 
 Attention: Mr. Jinsheng Ren 
  

 8 

 and to Indemnitee at: 
 [Name] 
 [Address] 
 [Address] 
 [Address] 
 Notice of change of address shall be effective only when done in accordance with this Section. 
 8.
Certain Relationships. The obligations and rights created under this Agreement shall not be affected by any amendment to the Company’s Articles of Association or any other agreement or instrument to which Indemnitee is not a party, and
shall not diminish any other rights which Indemnitee now or in the future has against the Company or any other person or entity. 
 9.
Acknowledgment. The Company expressly acknowledges that it has entered into this Agreement and assumed the obligations imposed on the Company under this Agreement in order to induce Indemnitee to serve or to continue to serve as a director or
officer and acknowledges that Indemnitee is relying on this Agreement in serving or continuing to serve in such capacity. The Company further agrees to stipulate in any court proceeding that the Company is bound by all of the provisions of this
Agreement. 
 10. Period of Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right
of the Company against Indemnitee, or Indemnitee’s estate, heirs, executors, administrators or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of
action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such
cause of action, such shorter period shall govern. 
 11. Entire Agreement. This Agreement constitutes the entire agreement and
supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof. 
 (Signature page follows) 
  

 9 

 IN WITNESS WHEREOF, the parties hereto execute this Agreement as of the date first written above. 
  

	
	COMPANY
	
	 Simcere Pharmaceutical Group

	
	  

	 Name:

	 Title:

	
	 INDEMNITEE

	
	  

	 Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]